• Explore /
  • Videos & Slides
  • / Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).

Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).

Abstract Video & Slides

Presenter

null

Eiji Kikuchi, PhD

St. Marianna University School of Medicine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2024 ASCO Breakthrough

Session Type

Rapid Oral Abstract Session

Session Title

Rapid Oral Abstract Session B: Trials and Omics

Track

Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Thoracic Cancers

Sub Track

Antibody Drug Conjugates

Clinical Trial Registration Number

NCT04223856

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 108)

DOI

10.1200/JCO.2024.42.23_suppl.108

Abstract #

108

Abstract Disclosures

Similar Videos & Slides

Speaker: Shilpa Gupta, MD

Speaker: Michiel Simon Van Der Heijden, MD, PhD

Speaker: Matthew I. Milowsky, MD, FASCO

Speaker: Terence W. Friedlander, MD